Compare CMCO & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCO | VIR |
|---|---|---|
| Founded | 1875 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 1.5B |
| IPO Year | 2002 | 2019 |
| Metric | CMCO | VIR |
|---|---|---|
| Price | $19.20 | $9.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $21.00 | $19.43 |
| AVG Volume (30 Days) | 740.2K | ★ 1.5M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $936,240,000.00 | $68,556,000.00 |
| Revenue This Year | $19.73 | $270.22 |
| Revenue Next Year | $82.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.27 | N/A |
| 52 Week Low | $11.99 | $4.25 |
| 52 Week High | $24.40 | $11.66 |
| Indicator | CMCO | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 51.93 |
| Support Level | $13.66 | $8.43 |
| Resistance Level | $19.80 | $9.80 |
| Average True Range (ATR) | 1.37 | 0.40 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 58.84 | 58.10 |
Columbus McKinnon Corp is a world'wide designer, manufacturer and marketer of intelligent motion solutions for material handling that move the world forward and improve lives by efficiently and ergonomically moving, lifting, positioning and securing materials. Key products include hoists, crane components, precision conveyor systems, rigging tools, light rail workstations and digital power and motion control systems. These are relevant, professional-grade solutions that solve its customers critical material handling requirements.The Company has one operating and reportable segment. It has presence in United State, Germany, Europe, Middle East, and Africa (Excluding Germany), Canada, Asia Pacific, and Latin America. It has majority of sales from United States.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.